STOCKHOLM, September 15, 2015 /PRNewswire/ --
This material is intended for global medical media only.
For journalistic assessment and preparation before publication.
New data presented today at the 51st annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes receiving the U200 formulation of Tresiba(R) (insulin degludec) experienced significantly lower rates of confirmed hypoglycaemia and significantly reduced mean fasting blood glucose compared to those receiving insulin glargine U1001. Tresiba(R) U200 is twice as concentrated as U100, allowing patients to inject up to 160 units in a single injection, rather than in two separate injections.
"These findings provide valuable insights to physicians treating patients with type 2 diabetes, many of whom require higher doses of insulin," commented Dr Mark Warren, lead study investigator. "The more concentrated formulation of Tresiba(R) also means fewer injections, which will be a welcome option for those patients who require higher than 80 units."
The 32-week, open-label, crossover, treat-to-target trial compared the safety, efficacy and patient-reported outcomes of Tresiba(R) U200 to insulin glargine U100 in patients who might benefit from a low-volume basal insulin. In the study, patients with type 2 diabetes also reported higher satisfaction with Tresiba(R) U200, highlighting an overall preference versus insulin glargine U100. Patients receiving the more concentrated formulation of Tresiba(R) also reported numerically lower cases of nocturnal hypoglycaemia and lower weight change and rated the delivery device FlexTouch(R) significantly better for function1.
After 16 weeks, the study demonstrated1:
- Tresiba(R) U200 delivered non-inferiority to insulin glargine with respect to
change in patient blood glucose levels
- Significantly reduced mean fasting plasma glucose with Tresiba(R) U200 versus insulin
glargine (-0.82 mmol/L vs -0.05 mmol/L, p